WO2024089667 - ARIMOCLOMOL COMPOSITIONS FOR USE IN TREATING NIEMANN PICK DISEASE TYPE C (NPC)
National phase entry:
Publication Number
WO/2024/089667
Publication Date
02.05.2024
International Application No.
PCT/IB2023/060866
International Filing Date
27.10.2023
Title **
[English]
ARIMOCLOMOL COMPOSITIONS FOR USE IN TREATING NIEMANN PICK DISEASE TYPE C (NPC)
[French]
COMPOSITIONS D'ARIMOCLOMOL DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT DE LA MALADIE DE NIEMANN PICK DE TYPE C (NPC)
Applicants **
ZEVRA DENMARK A/S
Inventors
PEDERSON, Mette Lund
INGEMANN, Linda
Priority Data
63/419,985
27.10.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2234 | |
| EPO | Filing, Examination, Granting | 9762 | |
| Japan | Filing, Examination, Granting | 2214 | |
| South Korea | Filing, Examination, Granting | 2197 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,147
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a pharmaceutical composition or formulation of arimoclomol citrate, either in monotherapy or in combination treatment therapy with miglustat, for use in one or more methods of treating Niemann Pick disease, type C (NPC) in a human patient. The present invention additionally relates arimoclomol for use in methods of treating NPC in a human patient, via dispersion or suspension of a pharmaceutical composition comprising a formulation of arimoclomol, specifically arimoclomol citrate, in at least one liquid or at least one solid medium prior to administration to the patient. The present disclosure also relates to the biomarkers and metabolites of arimoclomol.[French]
La présente invention concerne une composition pharmaceutique ou une formulation de citrate d'arimoclomol, soit en monothérapie soit en polythérapie avec du miglustat, destinée à être utilisée dans une ou plusieurs méthodes de traitement de la maladie de Niemann Pick, de type C (NPC) chez un patient humain. La présente invention concerne en outre de l'arimoclomol destiné à être utilisé dans des méthodes de traitement de la NPC chez un patient humain, par l'intermédiaire d'une dispersion ou d'une suspension d'une composition pharmaceutique comprenant une formulation d'arimoclomol, en particulier de citrate d'arimoclomol, dans au moins un liquide ou au moins un milieu solide avant l'administration au patient. La présente divulgation concerne également les biomarqueurs et les métabolites de l'arimoclomol.